GRI Bio Enters Into ~$80M Asset Purchase Agreement With Aardvark Therapeutics For The Sale Of Legacy Asset, ADAIR
Portfolio Pulse from Benzinga Newsdesk
GRI Bio has entered into an asset purchase agreement with Aardvark Therapeutics for the sale of its legacy asset, ADAIR, for approximately $80 million.
August 23, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GRI Bio has sold its legacy asset, ADAIR, to Aardvark Therapeutics for approximately $80 million. This could potentially free up resources for GRI Bio to focus on other projects.
The sale of ADAIR could potentially free up resources for GRI Bio to focus on other projects, which could be beneficial for the company in the long run. However, the impact of this sale on the company's short-term financial performance is uncertain.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100